{"id":973676,"date":"2026-06-18T09:23:07","date_gmt":"2026-06-18T13:23:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\/"},"modified":"2026-06-18T09:23:07","modified_gmt":"2026-06-18T13:23:07","slug":"new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\/","title":{"rendered":"New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer\u2019s Disease Accepted for Poster Presentation at the 2026 Alzheimer\u2019s Association International Conference (AAIC)"},"content":{"rendered":"
\n

MIAMI, June 18, 2026 (GLOBE NEWSWIRE) — Longeveron Inc.<\/a> (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that additional analysis of data from the Phase 2a clinical trial evaluating its stem cell therapy laromestrocel<\/a> in mild Alzheimer\u2019s disease<\/a> has been accepted for Poster Presentation at the 2026 Alzheimer\u2019s Association International Conference\u00ae<\/sup> (AAIC\u00ae<\/sup>)<\/a>, to be held July 12-15, 2026 in London, United Kingdom and online.<\/p>\n\n\n\n\n\n\n\n
\n
\n Poster Presentation (Exhibit Hall)<\/u>
\n <\/strong>
\n \n <\/td>\n<\/tr>\n
\n Date:<\/strong>\n <\/td>\nMonday, July 13, 2026<\/td>\n<\/tr>\n
\n Time:<\/strong>\n <\/td>\n7:30am \u2013 4:15pm BST<\/td>\n<\/tr>\n
\n Session:<\/strong>\n <\/td>\nIn-Person Posters Tuesday; Drug Development: Human<\/td>\n<\/tr>\n
\n Topic:<\/strong>\n <\/td>\nLaromestrocel in Mild Alzheimer\u2019s Disease: Additional Phase 2a Clinical Data Analysis<\/td>\n<\/tr>\n
\u00a0<\/td>\n<\/tr>\n<\/table>\n

Results from the CLEAR MIND Phase 2a clinical trial, which support the therapeutic potential of laromestrocel in the treatment of mild Alzheimer\u2019s disease and provided evidence-based support for further clinical development, were published<\/a> in the peer-reviewed journal Nature Medicine<\/em><\/a> in March 2025.<\/p>\n

\n About Longeveron Inc.<\/strong>\n <\/p>\n

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company\u2019s lead investigational product is laromestrocel (Lomecel-B\u2122<\/sup>), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer\u2019s disease, Pediatric Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program – Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program – Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com<\/u><\/a> or follow Longeveron on LinkedIn<\/u><\/a>, X<\/u><\/a>, and Instagram<\/u><\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management\u2019s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpects,\u201d \u201cintend,\u201d \u201clooks to,\u201d \u201cmay,\u201d \u201con condition,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cpreliminary,\u201d \u201cproject,\u201d \u201csee,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative thereof or comparable terminology, although not all forward-looking statements contain these words, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; our ability to successfully transition toward a more capital-efficient, asset-light operating model; our ability to secure one or more strategic licensing partnerships for our stem cell therapy laromestrocel in our development programs; the ability to reach alignment with the FDA on a potential path toward regulatory approval; receipt of trial results and other available evidence sufficient to support the Company filing a BLA following the readout of top-line results of the ELPIS II data; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; market and other conditions, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our investigational product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for certain of our investigational product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the investigational product candidate for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our investigational product candidates; our ability to obtain and maintain regulatory approval of our investigational product candidates in the U.S. and other jurisdictions; our plans relating to the further development of our investigational product candidates, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.<\/p>\n

Further information relating to factors that may impact the Company\u2019s results and forward-looking statements are disclosed in the Company\u2019s filings with the Securities and Exchange Commission, including Longeveron\u2019s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 17, 2026, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The Company operates in highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company\u2019s management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release based on information available as of the date of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.<\/p>\n

\n Investor and Media Contact:<\/strong>
\n
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

MIAMI, June 18, 2026 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that additional analysis of data from the Phase 2a clinical trial evaluating its stem cell therapy laromestrocel in mild Alzheimer\u2019s disease has been accepted for Poster Presentation at the 2026 Alzheimer\u2019s Association International Conference\u00ae (AAIC\u00ae), to be held July 12-15, 2026 in London, United Kingdom and online. Poster Presentation (Exhibit Hall) Date: Monday, July 13, 2026 Time: 7:30am \u2013 4:15pm BST Session: In-Person Posters Tuesday; Drug Development: Human Topic: Laromestrocel in Mild Alzheimer\u2019s Disease: Additional Phase 2a Clinical Data Analysis \u00a0 Results from the CLEAR MIND Phase 2a clinical trial, which … <\/p>\n

Continue reading “New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer\u2019s Disease Accepted for Poster Presentation at the 2026 Alzheimer\u2019s Association International Conference (AAIC)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-973676","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNew Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer\u2019s Disease Accepted for Poster Presentation at the 2026 Alzheimer\u2019s Association International Conference (AAIC) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer\u2019s Disease Accepted for Poster Presentation at the 2026 Alzheimer\u2019s Association International Conference (AAIC) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MIAMI, June 18, 2026 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that additional analysis of data from the Phase 2a clinical trial evaluating its stem cell therapy laromestrocel in mild Alzheimer\u2019s disease has been accepted for Poster Presentation at the 2026 Alzheimer\u2019s Association International Conference\u00ae (AAIC\u00ae), to be held July 12-15, 2026 in London, United Kingdom and online. Poster Presentation (Exhibit Hall) Date: Monday, July 13, 2026 Time: 7:30am \u2013 4:15pm BST Session: In-Person Posters Tuesday; Drug Development: Human Topic: Laromestrocel in Mild Alzheimer\u2019s Disease: Additional Phase 2a Clinical Data Analysis \u00a0 Results from the CLEAR MIND Phase 2a clinical trial, which … Continue reading "New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer\u2019s Disease Accepted for Poster Presentation at the 2026 Alzheimer\u2019s Association International Conference (AAIC)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-18T13:23:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0ODk4MyM3NjY3NTk5IzIyMDcwNjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer\u2019s Disease Accepted for Poster Presentation at the 2026 Alzheimer\u2019s Association International Conference (AAIC)\",\"datePublished\":\"2026-06-18T13:23:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\\\/\"},\"wordCount\":1100,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0ODk4MyM3NjY3NTk5IzIyMDcwNjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\\\/\",\"name\":\"New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer\u2019s Disease Accepted for Poster Presentation at the 2026 Alzheimer\u2019s Association International Conference (AAIC) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0ODk4MyM3NjY3NTk5IzIyMDcwNjA=\",\"datePublished\":\"2026-06-18T13:23:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0ODk4MyM3NjY3NTk5IzIyMDcwNjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc0ODk4MyM3NjY3NTk5IzIyMDcwNjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer\u2019s Disease Accepted for Poster Presentation at the 2026 Alzheimer\u2019s Association International Conference (AAIC)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer\u2019s Disease Accepted for Poster Presentation at the 2026 Alzheimer\u2019s Association International Conference (AAIC) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\/","og_locale":"en_US","og_type":"article","og_title":"New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer\u2019s Disease Accepted for Poster Presentation at the 2026 Alzheimer\u2019s Association International Conference (AAIC) - Market Newsdesk","og_description":"MIAMI, June 18, 2026 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that additional analysis of data from the Phase 2a clinical trial evaluating its stem cell therapy laromestrocel in mild Alzheimer\u2019s disease has been accepted for Poster Presentation at the 2026 Alzheimer\u2019s Association International Conference\u00ae (AAIC\u00ae), to be held July 12-15, 2026 in London, United Kingdom and online. Poster Presentation (Exhibit Hall) Date: Monday, July 13, 2026 Time: 7:30am \u2013 4:15pm BST Session: In-Person Posters Tuesday; Drug Development: Human Topic: Laromestrocel in Mild Alzheimer\u2019s Disease: Additional Phase 2a Clinical Data Analysis \u00a0 Results from the CLEAR MIND Phase 2a clinical trial, which … Continue reading \"New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer\u2019s Disease Accepted for Poster Presentation at the 2026 Alzheimer\u2019s Association International Conference (AAIC)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-18T13:23:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0ODk4MyM3NjY3NTk5IzIyMDcwNjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer\u2019s Disease Accepted for Poster Presentation at the 2026 Alzheimer\u2019s Association International Conference (AAIC)","datePublished":"2026-06-18T13:23:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\/"},"wordCount":1100,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0ODk4MyM3NjY3NTk5IzIyMDcwNjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\/","name":"New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer\u2019s Disease Accepted for Poster Presentation at the 2026 Alzheimer\u2019s Association International Conference (AAIC) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0ODk4MyM3NjY3NTk5IzIyMDcwNjA=","datePublished":"2026-06-18T13:23:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0ODk4MyM3NjY3NTk5IzIyMDcwNjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc0ODk4MyM3NjY3NTk5IzIyMDcwNjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/new-phase-2a-clinical-data-analysis-of-stem-cell-therapy-laromestrocel-in-mild-alzheimers-disease-accepted-for-poster-presentation-at-the-2026-alzheimers-association-international-co\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer\u2019s Disease Accepted for Poster Presentation at the 2026 Alzheimer\u2019s Association International Conference (AAIC)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/973676","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=973676"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/973676\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=973676"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=973676"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=973676"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}